Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease

EBioMedicine

Volumn 19, Issue , 2017, Pages 139-145

  Li, Xuan ^a   Obeidat, Ma'en ^a   Zhou, Guohai ^a   Leung, Janice M ^a,b   Tashkin, Donald ^c   Wise, Robert ^d   Connett, John ^e   Joubert, Philippe ^f   Bossé, Yohan ^f,g   van den Berge, Maarten ^h   Brandsma, Corry Anke ^h   Nickle, David C ⁱ   Hao, Ke ^j   Paré, Peter D ^a,b   Sin, Don D ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f LAVAL UNIVERSITY   (Canada)

^g UNIVERSITÉ LAVAL   (Canada)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

COPD; FEV1; Gene expression; Ipratropium; Lung; Sex

Indexed keywords

IPRATROPIUM BROMIDE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE EXPRESSION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE TRAIT LOCUS; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; SPIROMETRY; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; SEXUAL CHARACTERISTICS; TREATMENT OUTCOME;

ADULT; BODY MASS INDEX; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; FEMALE; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 85018427649     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2017.04.020     Document Type: Article

References (35)

1. Alagha, K., Palot, A., Sofalvi, T., et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther. Adv. Chron. Dis. 5:2 (2014), 85–98.
2. Anthonisen, N.R., Connett, J.E., Kiley, J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. Jama 272:19 (1994), 1497–1505.
3. Benowitz, N.L., Lessov-Schlaggar, C.N., Swan, G.E., Jacob, P. 3rd., Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 79:5 (2006), 480–488.
4. Calverley, P.M., Anderson, J.A., Celli, B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356:8 (2007), 775–789.
5. Cazzola, M., MacNee, W., Martinez, F.J., et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 31:2 (2008), 416–469.
6. Cazzola, M., Calzetta, L., Bettoncelli, G., Novelli, L., Cricelli, C., Rogliani, P., Asthma and comorbid medical illness. Eur. Respir. J. 38:1 (2011), 42–49.
7. Cazzola, M., Calzetta, L., Lauro, D., et al. Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. Respir. Med. 107:9 (2013), 1417–1422.
8. Cheyne, L., Irvin-Sellers, M.J., White, J., Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev., 9, 2015, CD009552.
9. Churg, A., Sin, D.D., Wright, J.L., Everything prevents emphysema: are animal models of cigarette smoke-induced chronic obstructive pulmonary disease any use?. Am. J. Respir. Cell Mol. Biol. 45:6 (2011), 1111–1115.
10. Cohen, J., Douma, W.R., Ten Hacken, N.H., Oudkerk, M., Postma, D.S., Physiology of the small airways: a gender difference?. Respir. Med. 102:9 (2008), 1264–1271.
11. Dransfield, M.T., Washko, G.R., Foreman, M.G., Estepar, R.S., Reilly, J., Bailey, W.C., Gender differences in the severity of CT emphysema in COPD. Chest 132:2 (2007), 464–470.
12. FirstWord Pharma. 2013. FirstWord Lists: Top 10 respiratory drugs 2012 and 2018: GlaxoSmithKline to remain the dominant force? Available at http://www.firstwordpharma.com/node/1145830#axzz4bbC0UqhP.
13. Gross, N.J., Ipratropium bromide. N. Engl. J. Med. 319:8 (1988), 486–494.
14. Hao, K., Bosse, Y., Nickle, D.C., et al. Lung eQTLs to help reveal the molecular underpinnings of asthma. PLoS genetics, 8(11), 2012 e1003029.
15. Kanner, R.E., Connett, J.E., Altose, M.D., et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am. J. Respir. Crit. Care Med. 150:4 (1994), 956–961.
16. Karakiulakis, G., Roth, M., Muscarinic receptors and their antagonists in COPD: anti-inflammatory and antiremodeling effects. Mediat. Inflamm., 2012, 2012, 409580.
17. Langdeau, J.B., Day, A., Turcotte, H., Boulet, L.P., Gender differences in the prevalence of airway hyperresponsiveness and asthma in athletes. Respir. Med. 103:3 (2009), 401–406.
18. Larcombe, A.N., Foong, R.E., Bozanich, E.M., et al. Sexual dimorphism in lung function responses to acute influenza A infection. Influenza Other Respir. Viruses 5:5 (2011), 334–342.
19. Ma, J., Ward, E.M., Siegel, R.L., Jemal, A., Temporal trends in mortality in the United States, 1969-2013. Jama 314:16 (2015), 1731–1739.
20. Magnussen, H., Disse, B., Rodriguez-Roisin, R., et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 371:14 (2014), 1285–1294.
21. Malerba, M., Montuschi, P., Non-invasive biomarkers of lung inflammation in smoking subjects. Curr. Med. Chem. 19:2 (2012), 187–196.
22. Martinez, F.J., Curtis, J.L., Sciurba, F., et al. Sex differences in severe pulmonary emphysema. Am. J. Respir. Crit. Care Med. 176:3 (2007), 243–252.
23. McGarry, M.E., Castellanos, E., Thakur, N., et al. Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma. Chest 147:6 (2015), 1591–1598.
24. McKenzie, R., Burton, M.D., Royce, S.G., Tang, M.L., Age and sex influences on airway hyperresponsiveness. J. Asthma 47:6 (2010), 651–654.
25. Montuschi, P., Ciabattoni, G., Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J. Med. Chem. 58:10 (2015), 4131–4164.
26. Montuschi, P., Macagno, F., Valente, S., Fuso, L., Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr. Med. Chem. 20:12 (2013), 1464–1476.
27. Montuschi, P., Malerba, M., Santini, G., Miravitlles, M., Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov. Today 19:12 (2014), 1928–1935.
28. Sheel, A.W., Guenette, J.A., Yuan, R., et al. Evidence for dysanapsis using computed tomographic imaging of the airways in older ex-smokers. J. Appl. Physiol. 107:5 (2009), 1622–1628.
29. Sin, D.D., Miravitlles, M., Mannino, D.M., et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur. Respir. J. 48:3 (2016), 664–673.
30. Statista, Top 20 respiratory products in the U.S. based on revenue in 2014–2015 (in million U.S. dollars). Available at https://www.statista.com/statistics/318251/revenue-of-top-20-respiratory-products-in-the-us/.
31. Tam, A., Churg, A., Wright, J.L., et al. Sex differences in airway remodeling in a mouse model of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 193:8 (2016), 825–834.
32. Tantisira, K.G., Colvin, R., Tonascia, J., et al. Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am. J. Respir. Crit. Care Med. 178:4 (2008), 325–331.
33. Tashkin, D.P., Altose, M.D., Bleecker, E.R., et al. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am. Rev. Respir. Dis. 145:2 Pt 1 (1992), 301–310.
34. Tashkin, D., Celli, B., Kesten, S., Lystig, T., Decramer, M., Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir. Med. 104:10 (2010), 1495–1504.
35. Vogelmeier, C.F., Criner, G.J., Martinez, F.J., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. Gold executive summary. Am. J. Respir. Crit. Care Med. 195:5 (2017), 557–582.